Determinants of long-term quality of life and voiding function of patients treated with radical prostatectomy or permanent brachytherapy for prostate cancer

BJU International

Volumn 94, Issue 7, 2004, Pages 1003-1009

  Bradley, Emily B ^a   Bissonette, Eric A ^a   Theodorescu, Dan ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Brachytherapy; Prostate cancer; Quality of life; Radical prostatectomy

Indexed keywords

PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; BRACHYTHERAPY; BRIEF SEXUAL FUNCTION INVENTORY; CONTROLLED STUDY; CORRELATION ANALYSIS; EXTERNAL BEAM RADIOTHERAPY; FUNCTIONAL ASSESSMENT OF CANCER THERAPY GENERAL QUESTIONNAIRE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MICTURITION; MONOTHERAPY; OBSTRUCTIVE SUBSCALE SYMPTOM SCORE; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SEXUAL FUNCTION; STATISTICAL ANALYSIS; SURGICAL TECHNIQUE; URINARY FUNCTION QUESTIONNAIRE FOR MEN AFTER RADICAL PROSTATECTOMY; URINE INCONTINENCE; VALIDATION PROCESS;

ADENOCARCINOMA; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; FOLLOW-UP STUDIES; HUMANS; IMPOTENCE; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY OF LIFE; URINARY INCONTINENCE;

EID: 9644265229     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.05094.x     Document Type: Article

References (25)

1. Krupski T, Petroni GR, Bissonette EA, Theodorescu D. Quality-of-life comparison of radical prostatectomy and interstitial brachytherapy in the treatment of clinically localized prostate cancer. Urology 2000; 55: 736-42
2. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, 5th edn. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997; 80: 1803-4
3. Cella DF, Tulsky DS, Gray G et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993; 11: 570-9
4. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association, Medical Care 1995; 33 (Suppl 4): AS145-55
5. Plante M, Corcos J, Gregoire I, Belanger MF, Brock G, Rossingol M. The International Prostate Symptom Score: physician versus self-administration in the quantification of symptomatology. Urology 1996; 47: 326-8
6. Herr HW. Quality of life of incontinent men after radical prostatectomy. J Urol 1994; 151: 652-4
7. O'Leary MP, Fowler FJ, Lenderking WR et al. A brief male sexual function inventory for urology. Urology 1995; 46: 697-706
8. Gray M, Petroni GR, Theodorescu D. Urinary function after radical prostatectomy: a comparison of the retropubic and perineal approaches. Urology 1999; 53: 881-91
9. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995; 31: 1341-6
10. Licht MR, Klein EA, Tuason L, Levin H. Impact of bladder neck preservation during radical prostatectomy on continence and cancer control. Urology 1994; 44: 883-7
11. Walsh PC. Radical prostatectomy, preservation of sexual function, cancer control. The controversy. Urol Clin North Am 1987; 14: 663-73
12. Ragde H. Brachytherapy (seed implantation) for clinically localized prostate cancer. J Surg Oncol 1997; 64: 79-81
13. Long J, Ervin L. The Huber-White method to adjust the variance-covariance matrix of a fit from maximum likelihood or least squares. Am Statistician 2000; 54: 217-24
14. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method. BMJ 1995; 310: 170
15. Spiessens B, Lesaffre E, Verbeke G, Kim K. Group sequential methods for an ordinal logistic random-effects model under misspecification. Biometrics 2002; 58: 569-75
16. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York: Chapman & Hall, 1993
17. Goodman SN, Berlin JA. The use of predicted confidence intervals when planning experiments and the misuse of power when interpreting results. Ann Intern Med 1994; 121: 200-6
18. Davis DL. Prostate cancer treatment with radioactive seed implantation. AORN J 1998; 68: 18, 21-3, 26-30, 42, 45
19. Bacon CG, Giovannucci E, Testa M, Kawachi I. The impact of cancer treatment on quality of life outcomes for patients with localized prostate cancer. J Urol 2001; 166: 1804-10
20. Wei JT, Dunn RL, Sandler HM et al. Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer. J Clin Oncol 2002; 20: 557-66
21. Eastham JA, Kattan MW, Rogers E et al. Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996; 156: 1707-13
22. Fulmer BR, Bissonette EA, Petroni GR, Theodorescu D. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer 2001; 91: 2046-55
23. Litwin MS, Flanders SC, Pasta DJ, Stoddard ML, Lubeck DP, Henning JM. Sexual function and bother after radical prostatectomy or radiation for prostate cancer: multivariate quality-of-life analysis from CaPSURE. Cancer Prostate Strategic Urologic Research Endeavor. Urology 1999; 54: 503-8
24. Potters L, Torre T, Fearn PA, Leibel SA, Kattan MW. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2001; 50: 1235-42
25. Nejat RJ, Rashid HH, Bagiella E, Katz AE, Benson MC. A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol 2000; 164: 1891-4